BMS 986207

Drug Profile

BMS 986207

Alternative Names: Anti-TIGIT antibody - Bristol Myers Squibb; BMS-986207; ONO-4686

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Nov 2016 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Combination therapy, Monotherapy) in USA (Parenteral) (NCT02913313)
  • 27 Sep 2016 Preclinical trials in Solid tumours in USA before September 2016 (Parenteral)
  • 27 Sep 2016 Bristol-Myers Squibb and Ono Pharmaceutical plans a phase I/II trial for Solid tumours (Second-line therapy or greater, Monotherapy, Combination therapy) in US, Australia, Canada and Japan (NCT02913313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top